1268692-80-3

Upstream product

• 93102-05-7 N-benzyl-N-(methoxymethyl)-N-[(trimethylsilyl)methyl]amine 
• 1115962-21-4 (R)-1-[(3R,4S)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethanol 
• 51173-05-8 5-fluoropyridin-2-ol 
• 1115961-72-2 1-(1-benzyl-2,5-dihydro-1H-pyrrol-3-yl)-ethanone 
• 1115962-15-6 1-[(3R,4 S)-1-Benzyl-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethanone 

Downstream Products

• 1268692-79-0 2-{(S)-1-[(3R,4S)-4-(4-chloro-phenyl)-pyrrolidin-3-yl]-ethoxy}-5-fluoro-pyridine 
• 1268692-82-5 {(3S,4R)-3-(4-chloro-phenyl)-4-[1-((S)-5-fluoro-pyridin-2-yloxy)-ethyl]-pyrrolidin-1-yl}-piperidin-4-yl-methanone 

Relevant academic research and scientific papers

PYRROLIDINES AS NK3 RECEPTOR ANTAGONISTS

The present invention relates to a compounds of formula I wherein R1, R2, Ar1, Ar2, R′, R″, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson''s disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

PYRROLIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS

The present invention relates to a compounds of formula (I) wherein R1 is hydrogen or lower alkyl; R2 is hydrogen, lower alkyl, lower alkyl substituted by halogen or is halogen or CN, and may be independently from each other if o is